Plasmid DNA Manufacturing Market Size Worth $1.51 Billion by 2030: Grand View Research, Inc.
SAN FRANCISCO, Oct. 5, 2022/PRNewswire/ -- The global plasmid DNA manufacturing market size is expected to reach USD 1.51 billion by 2030, registering a CAGR of 13.71% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.
Key Industry Insights & Findings from the report:
The GMP grade type segment held the largest revenue share in 2021. GMP-grade plasmid DNAs are broadly utilized in pre-clinical trials in gene therapy or vaccination including bio distribution and toxicology studies.
The clinical therapeutics segment dominated the global industry in 2021 owing to the increased importance of plasmid DNA for clinical research applications in genetic vaccination.
The infectious diseases segment held a significant revenue in 2021. DNA plasmid is effectively utilized in the treatment of several infectious disorders as it delivers a strong immunity via vaccine antigen and prevents pathogen infections.
The cell & gene therapy application segment led the industry in 2021 owing to the high demand for gene therapy for the treatment of several inherited diseases and genetic disorders.
North America was the dominant regional market in 2021 due to improved healthcare infrastructure, high disposable income, presence of a substantial number of centers and institutes that are engaged in R&D of advanced therapies, and increased adoption of advanced therapies in the region.
Asia Pacific is anticipated to register the fastest CAGR during the forecast years on account of the increasing R&D activities in this field and the presence of key players.
According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world's first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.
Circular DNA is used in India's ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.
Plasmid DNA Manufacturing Market Segmentation
Grand View Research has segmented the global plasmid DNA manufacturing market based on grade, development phase, application, disease, and region:
Plasmid DNA Manufacturing Market - Grade Scope Outlook (Revenue, USD Million, 2018 - 2030)
R&D Grade
GMP Grade
Plasmid DNA Manufacturing Market - Development Phase Scope Outlook (Revenue, USD Million, 2018 - 2030)
Pre-clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
Plasmid DNA Manufacturing Market - Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
DNA Vaccines
Cell & Gene Therapy
Immunotherapy
Others
Plasmid DNA Manufacturing Market - Disease Scope Outlook (Revenue, USD Million, 2018 - 2030)
Infectious Disease
Cancer
Genetic Disorder
Plasmid DNA Manufacturing Market - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
List of Key Players of Plasmid DNA Manufacturing Market
Charles River Laboratories
VGXI, Inc.
Aldevron
Kaneka Corp.
Nature Technology
Cell and Gene Therapy Catapult
Eurofins Genomics
Lonza
Luminous BioSciences, LLC
Akron Biotech
Check out more related studies published by Grand View Research:
Viral Vectors And Plasmid DNA Manufacturing Market - The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.
DNA Sequencing Market - The global DNA sequencing market size is expected to reach USD 11.2 billion by 2027, expanding at a CAGR of 11.4%, according to a new report by Grand View Research, Inc. The incorporation of Artificial Intelligence (AI) has increased the utility of genomic data in clinical practices and thus creates a new frontier in the advancement of genomic data analysis. In May 2020, Nvidia Corporation developed new AI tools, genomic sequencing software, and speech recognition technologies to aid the COVID-19 research efforts. Thus, AI accelerates the variant annotation and prioritization in the clinical diagnosis, which drives the market.
DNA & Gene Chip Market - The global DNA & gene chip market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., at an 11.4% CAGR during the forecast period. DNA and gene chips have gained much success in providing high throughput capabilities for comprehensive genome studies to enhance disease knowledge and target them. This technology has emerged as a valuable and promising solution across various aspects of disease management. These factors have been driving the market.
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
White Glove Placement, a leading provider of staffing solutions for healthcare facilities, is proud to announce its "Scoops of Gratitude" Free Ice Cream Truck to celebrate Nurses Week and show appreciation for the dedication and hard work of nurses...
Two El Camino Health hospitals in the South Bay have earned the highest ranking for patient safety from The Leapfrog Group, a national, not-for-profit, independent evaluator that measures excellence in patient care. This national distinction marks...
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the...
EVP Capital Inc. ("EVP Capital"), a capital pool company ("CPC") listed on the TSX Venture Exchange Inc. (the "Exchange"), is pleased to announce that it has entered into a non-binding letter of intent dated May 1, 2024 (the "LOI") with Sharp Edge...
Moonstone Nutrition, a pioneering nutraceutical company dedicated to the prevention of kidney stones, is thrilled to announce the launch of its latest investment campaign on StartEngine, one of the leading equity crowdfunding platforms. This exciting...